Glucose B.Braun (Glucose, Anhydrous)

Glucose B.Braun is indicated for clinical situations where rapid provision of carbohydrate energy is required to maintain metabolic stability.

• Management of documented hypoglycemia in hospitalized patients.
• Component of total parenteral nutrition regimens for patients unable to receive enteral feeding.
• Support during perioperative periods when oral intake is limited.
• Treatment of metabolic disorders that impair endogenous glucose production.
• Fluid and electrolyte replacement when combined with compatible intravenous solutions.
• Adjunctive therapy in critical care settings to maintain blood glucose levels during prolonged fasting.

Glucose B.Braun, when administered intravenously, may be associated with a range of adverse reactions that vary in frequency and clinical significance.

Common

• Local irritation at the infusion site.
• Mild hyperglycemia detectable on routine blood glucose monitoring.
• Transient nausea or vomiting.
• Fluid overload when administered in large volumes.
• Mild headache reported during rapid infusion.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Allergic reactions such as urticaria, rash, or anaphylaxis.
• Electrolyte disturbances, particularly hyponatremia or hypokalemia.
• Metabolic acidosis in patients with impaired lactate clearance.
• Hypotension secondary to rapid osmotic shifts.

Glucose B.Braun should be used with attention to patient‑specific factors and clinical conditions to minimize risks and ensure therapeutic effectiveness.

• Verify blood glucose levels before and during infusion to avoid excessive hyperglycemia.
• Adjust infusion rate in patients with renal or hepatic impairment.
• Use caution in individuals with known hypersensitivity to glucose solutions or excipients.
• Monitor fluid balance and electrolytes, especially sodium and potassium, during prolonged therapy.
• Avoid concurrent administration with incompatible intravenous drugs that may precipitate precipitation.
• Consider special dosing in neonates, infants, and pediatric patients under medical supervision.
• Document any adverse reactions promptly in the patient’s medical record.

Glucose B.Braun may interact with other intravenous agents or systemic medications, influencing its safety profile or therapeutic outcome.

Avoid

• Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring.
• Simultaneous infusion of calcium‑containing solutions that can cause precipitation.
• Use with hyperosmolar agents that may exacerbate fluid overload.
• Avoid mixing with acidic solutions that may degrade glucose stability.

Use with caution

• Concurrent use of diuretics, which may alter electrolyte balance during glucose infusion.
• Administration alongside catecholamines, as they can affect glucose metabolism.
• Overlap with other carbohydrate‑containing parenteral solutions, requiring careful calculation of total glucose load.
• Use cautiously in patients receiving beta‑blockers, as they may mask signs of hypoglycemia.